Literature DB >> 9800950

Translocation of profilaggrin N-terminal domain into keratinocyte nuclei with fragmented DNA in normal human skin and loricrin keratoderma.

A Ishida-Yamamoto1, H Takahashi, R B Presland, B A Dale, H Iizuka.   

Abstract

The terminal differentiation of epidermal keratinocytes from the granular to enucleated cornified layer involves drastic changes both in morphology and biochemistry. Profilaggrin is a keratinocyte-specific phosphoprotein expressed in the granular layer. Although keratinization has been regarded as a specialized form of apoptosis or programmed cell death, the mechanism for this cellular transition at the molecular level is not yet well understood. In this study, we used light and electron microscopic immunohistochemistry to investigate the localization of the profilaggrin domains during this process. Antibodies specific for the amino-terminal domains of profilaggrin showed localization in keratohyalin granules in the granular cells, but stained the nucleus in transition cells. In contrast, an antibody to filaggrin domains stained the cytoplasm in the transition cells. Nuclei that were positive to amino-terminal profilaggrin contained fragmented DNA, characteristic of apoptosis. In the epidermis of patients with progressive symmetric erythrokeratoderma carrying a mutation in the loricrin gene (loricrin keratoderma), the profilaggrin amino-terminal domains were packed within apoptotic nuclei together with loricrin aggregates and this persisted up to the parakeratotic superficial layer. The present study indicates that the amino-terminal profilaggrin domains are cleaved from the filaggrin repeats and transiently localized to the apoptotic nuclei just before the formation of enucleated stratum corneum in normal epidermis. This suggests a significant role for the profilaggrin amino-terminus in nuclear events associated with keratinocyte terminal differentiation. Disrupted apoptosis found in loricrin keratoderma might explain the marked parakeratotic hyperkeratosis characteristic of this disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9800950

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  16 in total

1.  Psoriasin (S100A7) expression and invasive breast cancer.

Authors:  S Al-Haddad; Z Zhang; E Leygue; L Snell; A Huang; Y Niu; T Hiller-Hitchcock; K Hole; L C Murphy; P H Watson
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 2.  Keratinocyte apoptosis in epidermal development and disease.

Authors:  Deepak Raj; Douglas E Brash; Douglas Grossman
Journal:  J Invest Dermatol       Date:  2006-02       Impact factor: 8.551

3.  Activation of vascular endothelial growth factor receptor 2 in a cellular model of loricrin keratoderma.

Authors:  Kozo Yoneda; Toshio Demitsu; Kozo Nakai; Tetsuya Moriue; Wataru Ogawa; Junsuke Igarashi; Hiroaki Kosaka; Yasuo Kubota
Journal:  J Biol Chem       Date:  2010-03-17       Impact factor: 5.157

4.  Deimination of human filaggrin-2 promotes its proteolysis by calpain 1.

Authors:  Chiung-Yueh Hsu; Julie Henry; Anne-Aurélie Raymond; Marie-Claire Méchin; Valérie Pendaries; Dany Nassar; Britta Hansmann; Stéfana Balica; Odile Burlet-Schiltz; Anne-Marie Schmitt; Hidenari Takahara; Carle Paul; Guy Serre; Michel Simon
Journal:  J Biol Chem       Date:  2011-04-29       Impact factor: 5.157

5.  Filaggrin in the frontline: role in skin barrier function and disease.

Authors:  Aileen Sandilands; Calum Sutherland; Alan D Irvine; W H Irwin McLean
Journal:  J Cell Sci       Date:  2009-05-01       Impact factor: 5.285

6.  Suppressing AP1 factor signaling in the suprabasal epidermis produces a keratoderma phenotype.

Authors:  Ellen A Rorke; Gautam Adhikary; Christina A Young; Dennis R Roop; Richard L Eckert
Journal:  J Invest Dermatol       Date:  2014-08-22       Impact factor: 8.551

7.  Knockdown of filaggrin in a three-dimensional reconstructed human epidermis impairs keratinocyte differentiation.

Authors:  Valérie Pendaries; Jeremy Malaisse; Laurence Pellerin; Marina Le Lamer; Rachida Nachat; Sanja Kezic; Anne-Marie Schmitt; Carle Paul; Yves Poumay; Guy Serre; Michel Simon
Journal:  J Invest Dermatol       Date:  2014-06-13       Impact factor: 8.551

8.  Structural properties of target binding by profilaggrin A and B domains and other S100 fused-type calcium-binding proteins.

Authors:  Alexander J Hinbest; Sa Rang Kim; Sherif A Eldirany; Ivan B Lomakin; Joseph Watson; Minh Ho; Christopher G Bunick
Journal:  J Dermatol Sci       Date:  2020-08-21       Impact factor: 4.563

9.  RanBPM interacts with psoriasin in vitro and their expression correlates with specific clinical features in vivo in breast cancer.

Authors:  Ethan D Emberley; R Daniel Gietz; J Darren Campbell; Kent T HayGlass; Leigh C Murphy; Peter H Watson
Journal:  BMC Cancer       Date:  2002-11-06       Impact factor: 4.430

10.  Crystal Structure of Human Profilaggrin S100 Domain and Identification of Target Proteins Annexin II, Stratifin, and HSP27.

Authors:  Christopher G Bunick; Richard B Presland; Owen T Lawrence; David J Pearton; Leonard M Milstone; Thomas A Steitz
Journal:  J Invest Dermatol       Date:  2015-03-11       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.